Form 4: HilleVax Director Aditya Kohli Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Director Aditya Kohli of HilleVax, Inc. executed sales of common stock between April 3rd and April 5th, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Aditya Kohli, a director of HilleVax, Inc., reported the sale of common stock in a Form 4 filing with the SEC.
- The transactions occurred between April 3rd and April 5th, 2024.
- A total of 18,000 shares were sold in three separate transactions.
- The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 12, 2023.
- The weighted average sale prices ranged from $14.44 to $14.9303 per share.
- Following these transactions, Kohli's direct ownership decreased from 801,776 to 789,776 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-existing trading plan. There is no indication of positive or negative implications for the company.
Industry Context
Sales by company directors are a normal part of corporate governance. The fact that these sales were executed under a pre-arranged 10b5-1 trading plan suggests they were planned in advance and not based on any immediate inside information.
Comparison to Industry Standards
- Comparing these transactions to similar insider sales at comparable biotech companies would require analyzing the volume of shares sold as a percentage of total shares outstanding, the timing relative to company announcements, and the reasons behind the sales.
- For example, if a CEO of a similar-sized biotech company, such as Icosavax (ICVX) or BioNTech (BNTX), sold a similar percentage of their holdings under a 10b5-1 plan, it might be viewed as a routine event.
- However, if the sales were significantly larger or occurred just before a negative clinical trial announcement, it could raise concerns.
Stakeholder Impact
- The stock sales could have a minor negative impact on shareholder sentiment, especially if investors are not aware of the pre-arranged trading plan.
- However, the impact is likely to be minimal given the relatively small volume of shares sold compared to the total outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 10/12/2023 | Date of adoption of the Rule 10b5-1 trading plan. |
| 04/03/2024 | Date of first reported transaction: Sale of 6,000 shares. |
| 04/04/2024 | Date of second reported transaction: Sale of 6,000 shares. |
| 04/05/2024 | Date of third reported transaction: Sale of 6,000 shares; Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.